The Drugs Controller General of India (DCGI) has given permission for the emergency use of 2-deoxy-D-glucose (2-DG) medicine as an adjunct therapy in moderate to severe Covid-19 cases.
An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad.
- Read more about DCGI approves 2-DG medicine for moderate to severe COVID-19 cases
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/dcgi-approves-2-dg-medicine-for-moderate-to-severe-covid-19-cases
No comments:
Post a Comment